| 000 | 01732 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515170907.0 | ||
| 264 | 0 | _c20090810 | |
| 008 | 200908s 0 0 eng d | ||
| 022 | _a1522-1555 | ||
| 024 | 7 |
_a10.1152/ajpendo.90632.2008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRemels, A H V | |
| 245 | 0 | 0 |
_aPPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. _h[electronic resource] |
| 260 |
_bAmerican journal of physiology. Endocrinology and metabolism _cJul 2009 |
||
| 300 |
_aE174-83 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCytokines _xpharmacology |
| 650 | 0 | 4 |
_aDown-Regulation _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xpharmacology |
| 650 | 0 | 4 |
_aInflammation Mediators _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuscle, Skeletal _xdrug effects |
| 650 | 0 | 4 |
_aNF-kappa B _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPPAR gamma _xagonists |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 650 | 0 | 4 | _aRosiglitazone |
| 650 | 0 | 4 |
_aThiazoles _xpharmacology |
| 650 | 0 | 4 |
_aThiazolidinediones _xpharmacology |
| 650 | 0 | 4 |
_aTranscriptional Activation _xdrug effects |
| 700 | 1 | _aLangen, R C J | |
| 700 | 1 | _aGosker, H R | |
| 700 | 1 | _aRussell, A P | |
| 700 | 1 | _aSpaapen, F | |
| 700 | 1 | _aVoncken, J W | |
| 700 | 1 | _aSchrauwen, P | |
| 700 | 1 | _aSchols, A M W J | |
| 773 | 0 |
_tAmerican journal of physiology. Endocrinology and metabolism _gvol. 297 _gno. 1 _gp. E174-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1152/ajpendo.90632.2008 _zAvailable from publisher's website |
| 999 |
_c18845924 _d18845924 |
||